OncoBone Ventures Ltd and Origenis GmbH, headquartered in Planegg, Germany, have signed a Framework Agreement to develop novel therapies targeting cancer bone metastasis, addressing a significant unmet medical need. Currently, there are no effective treatments for bone metastases, which affect 70-90% of advanced breast and prostate cancer patients, with less than 5% surviving beyond five years post-diagnosis.
Origenis leverages its cutting-edge Artificial Intelligence (AI) driven technology platform MolMind®·MOREsystem®·BRAINstorm™ to design innovative targeted small-molecule therapies. This technology platform addresses and optimizes highly specific distribution properties of drug candidates to selected target tissues of interest like bone, brain, and eye. Origenis has developed preclinical assets that have shown promising anti-metastatic potential in initial animal studies.
OncoBone Ventures is at the forefront of developing therapies for cancer bone metastasis using its proprietary osteoimmuno-oncology© (OIO) concept and preclinical Bone Metastasis Technology Platform©, a clinically predictive tool for evaluating the efficacy of therapeutic candidates against bone metastases.
“We are very impressed with the AI-driven technology platform of Origenis, and we are excited to partner with Origenis to evaluate the preclinical efficacy of their outstanding assets on bone metastases,” said Jussi Halleen, CEO of OncoBone Ventures and continued, “Together, we have a high probability of success in advancing these assets towards clinical development.”
Michael Thormann, CEO of Origenis, added, “We are delighted to collaborate with OncoBone Ventures, whose deep expertise in the bone metastasis field will maximize the likelihood of success in addressing this challenging unmet medical need. This strategic partnership is crucial to effectively advance the development of our novel small-molecule assets for bone metastasis.”
More information about Origenis can be found at https://www.origenis.de/
If you are interested to learn more, please reach out via https://www.oncobonetherapeutics.com/contact-us/.
